Core Viewpoint - The sales efforts for Didasanib by Jingxin Pharmaceutical are proceeding normally, with a focus on enhancing patient accessibility and providing new treatment solutions through hospital admissions and academic promotion activities [1] Company Summary - Jingxin Pharmaceutical (002020) is actively engaged in the sales of Didasanib, indicating a commitment to improving patient access to this treatment option [1]

Core Viewpoint - Jingxin Pharmaceutical (002020.SZ) has submitted its application for the approval of its drug, Calcitonin Salts, which is currently pending approval [1] Company Summary - Jingxin Pharmaceutical is actively pursuing the approval of its hydrochloride formulation of Calcitonin Salts, indicating a step forward in its product pipeline [1]

Core Viewpoint - Jingxin Pharmaceutical (002020.SZ) has submitted its application for the approval of its drug, Calcitonin Salts, which is currently pending approval [1] Company Summary - Jingxin Pharmaceutical is actively pursuing the approval of its hydrochloride formulation of Calcitonin Salts, indicating a strategic move to expand its product offerings in the pharmaceutical market [1]

Core Viewpoint - Jingxin Pharmaceutical's stock price has shown volatility, with a year-to-date increase of 46.92% but a recent decline in the last 20 days by 6.82% [2] Group 1: Stock Performance - As of November 4, Jingxin Pharmaceutical's stock price was 18.32 CNY per share, with a market capitalization of 15.774 billion CNY [1] - The stock has experienced a 1.38% increase over the last five trading days and a 1.16% increase over the last 60 days [2] - The company has appeared on the trading leaderboard once this year, with a net buy of 1.11 billion CNY on July 4 [2] Group 2: Financial Performance - For the period from January to September 2025, Jingxin Pharmaceutical reported a revenue of 3.048 billion CNY, a year-on-year decrease of 5.00%, while the net profit attributable to shareholders was 576 million CNY, reflecting a slight increase of 0.10% [2] - Cumulative cash dividends since the company's A-share listing amount to 2.11 billion CNY, with 801 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 13.08% to 22,300, with an average of 32,438 circulating shares per shareholder, an increase of 15.05% [2] - The seventh largest circulating shareholder is Hong Kong Central Clearing Limited, holding 7.4588 million shares, down by 2.1904 million shares from the previous period [3] Group 4: Business Overview - Jingxin Pharmaceutical, established on February 13, 1999, and listed on July 15, 2004, specializes in the research, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [2] - The company's main business revenue composition is 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [2] - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and preparations, and is involved in various concept sectors including ophthalmology, cancer treatment, generic drugs, innovative drugs, and biomedicine [2]

Core Viewpoint - Jingxin Pharmaceutical is a well-known domestic pharmaceutical company specializing in the fields of mental health and cardiovascular diseases, with a comprehensive business model covering chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [1] Business Performance - In Q3 2025, Jingxin Pharmaceutical reported a revenue of 3.048 billion yuan, ranking 24th among 110 companies in the industry, with the top company, East China Pharmaceutical, generating 32.664 billion yuan [2] - The net profit for the same period was 581 million yuan, placing the company 16th in the industry, while the leading company, Hengrui Medicine, achieved a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, Jingxin Pharmaceutical's debt-to-asset ratio was 28.74%, down from 31.73% year-on-year, and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for the same period was 50.07%, slightly down from 51.11% year-on-year, and lower than the industry average of 57.17% [3] Executive Compensation - The chairman and president, Lv Gang, received a salary of 1.4836 million yuan in 2024, a decrease of 151,900 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.08% to 22,300, while the average number of circulating A-shares held per shareholder increased by 15.05% to 32,400 [5] - The top ten circulating shareholders included Hong Kong Central Clearing Limited, which held 7.4588 million shares, a decrease of 2.1904 million shares from the previous period [5] Future Outlook - The company is focusing on the mental health and cardiovascular sectors, with expectations for double-digit growth in overall performance, driven by the launch of innovative drugs [5] - Projected revenues for 2025, 2026, and 2027 are 4.565 billion, 5.124 billion, and 5.770 billion yuan, respectively, with net profits of 791 million, 905 million, and 1.025 billion yuan [5] - Guotai Junan Securities noted that the company’s non-recurring profit exceeded expectations, with significant growth in foreign trade revenue and advancements in its innovative drug pipeline [6]

证券代码：002020 证券简称：京新药业 公告编号：2025059 浙江京新药业股份有限公司 关于股份回购进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、回购股份方案的基本情况 浙江京新药业股份有限公司(以下简称"公司")于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 20,000 万元(含)，不超过人民币 40,000 万元（含），回购价格不超过 14.80 元/股（含），若按回购总金额上、 下限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年 1 月 10 日 在 《 证 券 时 报 ...

Core Viewpoint - The company plans to repurchase shares through a dedicated securities account, indicating a strategy to enhance shareholder value and confidence in the company's future performance [1] Group 1: Share Repurchase Details - As of October 31, 2025, the company will repurchase a total of 47.2713 million shares, which represents 5.49% of the current total share capital [1] - The maximum purchase price for the shares is set at 14.41 CNY per share, while the minimum purchase price is 11.86 CNY per share [1] - The total amount allocated for the share repurchase is 609 million CNY, excluding transaction fees [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Jingxin Pharmaceutical in Q3 2025, showing a revenue decline but a slight increase in net profit [1] - The company's revenue for the first three quarters of 2025 is approximately 3.048 billion yuan, representing a year-on-year decrease of 5% [1] - The net profit attributable to shareholders is about 576 million yuan, reflecting a year-on-year increase of 0.1% [1] - Basic earnings per share are reported at 0.7 yuan, which is a year-on-year increase of 4.48% [1] Group 2 - As of the report, Jingxin Pharmaceutical has a market capitalization of 15.6 billion yuan [2]

Financial Performance - Q3 2025 revenue was CNY 1,031,649,329.24, a decrease of 2.57% year-over-year, while year-to-date revenue reached CNY 3,048,192,079.46, down 5.00% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was CNY 187,732,848.96, an increase of 8.59% year-over-year, with year-to-date net profit at CNY 575,611,846.06, showing a slight increase of 0.10%[5] - Basic and diluted earnings per share for Q3 2025 were both CNY 0.23, reflecting a 15.00% increase compared to the same period last year[5] - Total operating revenue for the current period was ¥3,048,192,079.46, a decrease of 5.01% from ¥3,208,743,897.71 in the previous period[19] - Operating profit for the current period was ¥664,258,601.66, slightly down from ¥671,815,265.63, reflecting a decrease of 1.04%[19] - Net profit before tax was ¥664,916,102.75, compared to ¥676,464,298.28 in the previous period, indicating a decline of 1.61%[19] - The net profit attributable to the parent company shareholders was CNY 575,611,846.06, a slight increase from CNY 575,012,790.33 in the previous period, reflecting a growth of 0.10%[20] - The total comprehensive income attributable to the parent company owners was CNY 575,497,372.10, compared to CNY 575,219,327.84 in the previous period, indicating a growth of 0.05%[20] - The basic and diluted earnings per share increased to CNY 0.70 from CNY 0.67, representing a growth of approximately 4.48%[20] Assets and Liabilities - Total assets at the end of Q3 2025 were CNY 7,978,648,630.10, a decrease of 5.90% from the end of the previous year[5] - Total assets decreased to ¥7,978,648,630.10 from ¥8,479,313,218.60, a reduction of 5.91%[18] - Total liabilities decreased to ¥2,293,129,014.28, down from ¥2,477,769,425.69, a decline of 7.43%[17] - Current assets increased to ¥3,142,880,026.72, up from ¥2,904,776,219.94, an increase of 8.19%[16] - Cash and cash equivalents rose to ¥452,279,163.55, compared to ¥316,266,734.17, reflecting a significant increase of 42.94%[16] - Inventory decreased slightly to ¥783,702,441.62 from ¥792,719,340.04, a decrease of 1.28%[16] - Unappropriated profits increased to ¥3,188,139,806.91 from ¥2,897,381,706.60, an increase of 10.03%[17] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 615,483,813.37, showing a slight increase of 0.46%[5] - The net cash flow from operating activities was CNY 615,483,813.37, slightly up from CNY 612,693,212.93 in the previous period, showing an increase of 0.46%[23] - Cash inflow from investment activities was CNY 2,038,840,858.84, down from CNY 3,277,371,692.31, a decrease of 37.87%[23] - The net cash flow from investing activities was CNY 514,465,812.65, reflecting a 133.66% increase due to reduced external investments[10] - The net cash flow from financing activities was CNY -981,378,371.85, a significant decrease of 529.57% primarily due to share repurchases[10] - The net cash flow from financing activities was negative CNY 981,378,371.85, worsening from negative CNY 155,879,600.17 in the previous period[23] - The total cash and cash equivalents at the end of the period amounted to CNY 433,628,680.58, an increase from CNY 204,186,009.58 in the previous period[23] - The company received CNY 2,846,292,493.75 in cash from sales of goods and services, a slight increase from CNY 2,838,651,137.39 in the previous period[22] - The company paid CNY 1,020,986,605.26 for goods and services, down from CNY 1,100,794,598.42, indicating a decrease of 7.25%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,318[11] - The top 10 shareholders hold a total of 60.77% of the shares, with the largest shareholder, Lü Gang, holding 20.77%[11] - The company has repurchased 47,271,295 shares, accounting for 5.49% of the total share capital, with a total transaction amount of 608.72 million RMB[13] - The maximum purchase price for repurchased shares was 14.41 RMB per share, while the minimum was 11.86 RMB per share[13] - The company plans to raise up to 150 million RMB through the fourth employee stock ownership plan, with a purchase price of 12.50 RMB per share[14] - The total number of shares involved in the employee stock ownership plan is 12 million shares[14] - The company has no preferred shareholders or significant changes in the top 10 shareholders due to margin trading[12] - The company’s major shareholder, Lü Gang, and his spouse hold 100% of the shares in Jingxin Holdings Group[11] - The company has not identified any other relationships among the top shareholders that would classify them as acting in concert[12] - The company’s repurchase account does not count towards the top 10 shareholders list[11] Income and Expenses - The company reported a significant increase of 1987.85% in current assets due to an increase in short-term deposits[9] - Investment income for the year-to-date period was CNY 16,687,385.45, a substantial increase of 179.54% year-over-year, attributed to higher dividend income[9] - The company experienced a 53.86% decrease in other income, primarily due to a reduction in government subsidies[9] - Total operating costs decreased to ¥2,417,770,049.29, down 7.33% from ¥2,608,110,283.39[19] - The company reported a decrease in other comprehensive income attributable to the parent company owners, with a net amount of CNY -114,473.96 compared to CNY 206,537.51 in the previous period[20]

Core Points - The Bioeconomy Index (970038) closed at 2277.51 points, down 0.16%, with a trading volume of 18.883 billion yuan and a turnover rate of 1.2% [1] - Among the index constituents, 23 stocks rose while 27 fell, with Iwubio leading the gainers at 6.71% and Meiya Optoelectronics leading the decliners at 3.02% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 225.09 yuan, and a market cap of 272.908 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 116.50 yuan, and a market cap of 47.525 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 31.97 yuan, and a market cap of 56.849 billion yuan [1] - Other notable constituents include Shishihistory (sz002252), Table Pharmaceutical (sz300347), and Muyuan Foods (sz002714) [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 871 million yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [3] - Key capital flows include: - Iwubio (300357) with a net inflow of 52.9277 million yuan from institutional investors [3] - Dabo Medical (002901) with a net inflow of 31.8434 million yuan from institutional investors [3] - Changchun High-tech (000661) with a net inflow of 27.6452 million yuan from institutional investors [3]